Modality
Cell Therapy
MOA
WEE1i
Target
PI3Kα
Pathway
STING
ObesityGA
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
~Mar 2021
→ ~Jun 2022
Phase 2
Sep 2022
→ Mar 2031
Phase 2Current
NCT03114519
1,853 pts·GA
2022-12→2031-03·Terminated
NCT05988083
1,097 pts·Obesity
2022-09→TBD·Not yet recruiting
2,950 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-135.0y awayPh3 Readout· GA
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2031-03-13 · 5.0y away
GA
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03114519 | Phase 2/3 | GA | Terminated | 1853 | VA |
| NCT05988083 | Phase 2/3 | Obesity | Not yet recr... | 1097 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| 369-789 | Hansoh Pharma | Phase 3 | PI3Kα | |
| Mavutuximab | Hansoh Pharma | Phase 2/3 | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |